TransMedics Group Inc. (TMDX)
TransMedics Stock Rises as Q4 Earnings & Revenues Beat Estimates
TMDX's fourth-quarter earnings depict strength in the company's net product revenues and services revenues. A rise in operating income bodes well for the stock.
TransMedics Group, Inc. (TMDX) Q4 2024 Earnings Call Transcript
TransMedics Group, Inc. (NASDAQ:TMDX ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group, Investor Relations Waleed Hassanein - President and Chief Executive Officer Gerardo Hernandez - Chief Financial Officer Conference Call Participants Allen Gong - JPMorgan Josh Jennings - TD Cowen Bill Plovanic - Canaccord Suraj Kalia - Oppenheimer Chris Pasquale - Nephron Research Matthew O'Brien - Piper Sandler David Rescott - Baird Mike Matson - Needham & Company Operator Good afternoon, and welcome to the TransMedics Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
TransMedics (TMDX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for TransMedics (TMDX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
TransMedics (TMDX) Q4 Earnings and Revenues Beat Estimates
TransMedics (TMDX) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.12 per share a year ago.
TransMedics' Revenue Surged 49.8% in Q4
TransMedics Group (TMDX -2.22%), a leader in organ transplant technology, released its fourth-quarter results on Feb. 27. The company reported diluted earnings per share (EPS) of $0.19, outpacing the $0.16 forecast by analysts, and revenue of $121.6 million exceeded the $109 million estimate.
TransMedics: Data Points To A Miss On Low Expectations, Followed By Big Improvement
TransMedics is expected to report disappointing Q4 results, with industry data suggesting it will likely miss and come in at the low end of guidance. The company's Q3 performance was poor, underperforming in Heart, Lung, and Liver transplants, leading to a significant loss of investor confidence. Despite a challenging Q4, early signs indicate a stronger start to 2025, potentially allowing management to provide more optimistic guidance for the year. Yet, I think they'll take the conservative route.
Curious about TransMedics (TMDX) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for TransMedics (TMDX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
TransMedics: Big Growth And Operational Advantages, Buy This Leading Medical Player
TransMedics Group is revolutionizing organ transplant therapy with its FDA-approved Organ Care System, enhancing donor organ preservation and transport. Despite a Q3 earnings miss and short-seller allegations, TMDX has shown remarkable five-year growth and operational advantages. TMDX's market share in heart, liver, and lung transplants has significantly increased, with future plans for kidney transplants and international expansion.
TMDX Stock Plunges 49.2% in Three Months: What's Behind the Downfall?
TransMedics is navigating macroeconomic challenges amid its focus on meaningful progress across each of its growth initiatives.
TMDX Stock Down Despite Responding to Misleading Short-Seller Report
TransMedics addresses the misleading claims made in a short-seller report issued by Scorpion Capital.
Why TransMedics Fell 15.7% This Week
Shares of organ transplant innovator TransMedics Group (TMDX -4.00%) fell 15.7% through Thursday trading, according to data from S&P Global Market Intelligence.
The Schall Law Firm Invites Investors With Losses To Join An Inquiry Into TransMedics Group Inc For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / January 15, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
